Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban [ID726]: committee papers
Table of contents
01 Pre-meeting briefing
02 Evidence Review Report
03 Evidence Review Group report - factual accuracy check
04 Erratum to the ERG report
05 Company submission - Bristol Myers-Squibb and Pfizer
06 NICE clarification Letter
07 Company response to the NICE clarification letter
08 Company response Addendum to the NICE clarification letter
09 Patient group - AntiCoagulation Europe(ACE)
10 Professional group - British Society for Haemostatis and Thrombosis
11 Professional group statment - British Thoracic Society
12 Professional group statament - Clinical Leaders of Thrombosis
13 Professional group statement - Royal College of Physcians
14 Professional Group statement - United Kingdom Clinical Pharmacy Association
15 Clinical expert statement - Lester
16 Clinical expert statement - Nokes
17 Patient expert statement - Hunt
18 Patient expert statement Eaton
Deep vein thrombosis, pulmonary embolism (treatment, secondary prevention) - apixaban [ID726]: committee papers
06 March 2015 (9.21 Mb 45 sec) |
This page was last updated: 04 March 2015